CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
5.52
0.36%
Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.021388 %
Charges from full value of position ($-4.06)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.021388%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000834 %
Charges from full value of position ($-0.16)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000834%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Valneva SE ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.5
Open* 5.55
1-Year Change* -3.14%
Day's Range* 5.52 - 5.62
52 wk Range 3.95-8.78
Average Volume (10 days) 218.22K
Average Volume (3 months) 7.08M
Market Cap 880.60M
P/E Ratio -100.00K
Shares Outstanding 138.22M
Revenue 372.96M
EPS -1.24
Dividend (Yield %) N/A
Beta 0.58
Next Earnings Date Sep 21, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 5.52 0.02 0.36% 5.50 5.63 5.39
Sep 28, 2023 5.50 0.03 0.55% 5.47 5.55 5.43
Sep 27, 2023 5.50 -0.06 -1.08% 5.56 5.69 5.49
Sep 26, 2023 5.53 -0.16 -2.81% 5.69 5.69 5.48
Sep 25, 2023 5.76 -0.42 -6.80% 6.18 6.25 5.68
Sep 22, 2023 5.84 0.01 0.17% 5.83 5.97 5.79
Sep 21, 2023 5.97 -0.21 -3.40% 6.18 6.42 5.90
Sep 20, 2023 6.20 0.27 4.55% 5.93 6.21 5.93
Sep 19, 2023 6.01 0.00 0.00% 6.01 6.07 5.89
Sep 18, 2023 6.05 0.00 0.00% 6.05 6.27 6.04
Sep 15, 2023 6.25 -0.02 -0.32% 6.27 6.52 6.23
Sep 14, 2023 6.28 0.14 2.28% 6.14 6.29 6.09
Sep 13, 2023 6.13 -0.05 -0.81% 6.18 6.21 6.09
Sep 12, 2023 6.21 -0.12 -1.90% 6.33 6.35 6.16
Sep 11, 2023 6.34 0.08 1.28% 6.26 6.40 6.24
Sep 8, 2023 6.27 -0.02 -0.32% 6.29 6.34 6.22
Sep 7, 2023 6.32 0.05 0.80% 6.27 6.46 6.27
Sep 6, 2023 6.34 0.14 2.26% 6.20 6.44 6.20
Sep 5, 2023 6.49 0.10 1.56% 6.39 6.54 6.39
Sep 4, 2023 6.44 0.07 1.10% 6.37 6.55 6.25

Valneva SE Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 361.303 348.086 110.321 126.196 113.035
Revenue 361.303 348.086 110.321 126.196 113.035
Cost of Revenue, Total 324.441 182.22 46.902 49.968 44.448
Gross Profit 36.862 165.866 63.419 76.228 68.587
Total Operating Expense 474.746 409.476 165.441 127.007 106.774
Selling/General/Admin. Expenses, Total 56.499 70.761 45.171 42.277 37.84
Research & Development 101.322 168.583 61.354 36.783 24.291
Depreciation / Amortization 4.9 5.4 4.9 4.464 4.331
Unusual Expense (Income) 0.038 5.742 26.41 0.092 0.007
Other Operating Expenses, Total -12.454 -23.23 -19.296 -6.577 -4.143
Operating Income -113.443 -61.39 -55.12 -0.811 6.261
Interest Income (Expense), Net Non-Operating -31.108 -8.281 -10.182 -0.059 -2.909
Other, Net -0.264 -0.308 -0.001
Net Income Before Taxes -144.815 -69.979 -65.302 -0.87 3.351
Net Income After Taxes -143.279 -73.425 -64.393 -1.744 3.263
Net Income Before Extra. Items -143.279 -73.425 -64.393 -1.744 3.263
Net Income -143.279 -73.425 -64.393 -1.744 3.263
Income Available to Common Excl. Extra. Items -143.279 -73.425 -64.393 -1.744 3.264
Income Available to Common Incl. Extra. Items -143.279 -73.425 -64.393 -1.744 3.264
Diluted Net Income -143.279 -73.425 -64.393 -1.744 3.264
Diluted Weighted Average Shares 115.474 97.6193 90.7572 91.7443 81.6002
Diluted EPS Excluding Extraordinary Items -1.24079 -0.75216 -0.70951 -0.01901 0.04
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -1.10971 -0.71392 -0.51936 -0.01836 0.04008
Total Adjustments to Net Income 0.001
Dilution Adjustment 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 33.508 268.079 156.678 93.224 21.847
Revenue 33.508 268.079 156.678 93.224 21.847
Cost of Revenue, Total 20.48 152.962 31.247 171.479 13.86
Gross Profit 13.028 115.117 125.431 -78.255 7.987
Total Operating Expense 50.082 231.112 63.361 243.634 40.269
Selling/General/Admin. Expenses, Total 19.024 33.704 12.488 24.095 7.804
Research & Development 14.065 53.039 23.502 51.883 20.689
Other Operating Expenses, Total -3.487 -8.585 -3.876 -3.869 -2.084
Operating Income -16.574 36.967 93.317 -150.41 -18.422
Interest Income (Expense), Net Non-Operating -1.673 -12.531 -21.007 -18.577 -7.117
Other, Net -0.029 -0.235
Net Income Before Taxes -18.247 24.407 72.31 -169.222 -25.539
Net Income After Taxes -18.127 28.214 72.418 -171.493 -26.041
Net Income Before Extra. Items -18.127 28.214 72.418 -171.493 -26.041
Net Income -18.127 28.214 72.418 -171.493 -26.041
Income Available to Common Excl. Extra. Items -18.127 28.214 72.418 -171.493 -26.041
Income Available to Common Incl. Extra. Items -18.127 28.214 72.418 -171.493 -26.041
Diluted Net Income -18.127 28.214 72.418 -171.493 -26.041
Diluted Weighted Average Shares 139.438 122.408 105.991 108.54 108.504
Diluted EPS Excluding Extraordinary Items -0.13 0.23049 0.68325 -1.58 -0.24
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.13 0.33638 0.68325 -1.55996 -0.24
Unusual Expense (Income) -0.008 0.046
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 424.66 585.832 308.427 129.162 125.972
Cash and Short Term Investments 286.532 346.642 204.394 64.439 77.084
Cash 286.533 346.642 173.109 39.439 57.085
Cash & Equivalents -0.001 -0.001
Short Term Investments 31.285 25 20
Total Receivables, Net 23.912 44.013 19.232 24.03 11.259
Accounts Receivable - Trade, Net 23.912 44.013 19.232 24.03 11.259
Total Inventory 35.104 124.098 26.933 25.772 22.727
Other Current Assets, Total 79.112 71.079 57.868 14.921 14.902
Total Assets 621.344 817.352 449.164 264.723 229.907
Property/Plant/Equipment, Total - Net 154.038 173.83 78.153 69.337 37.997
Property/Plant/Equipment, Total - Gross 221.187 215.283 111.31 100.5 75.012
Accumulated Depreciation, Total -67.148 -41.453 -33.156 -31.163 -37.015
Intangibles, Net 28.711 32.7 35.409 41.813 44.891
Other Long Term Assets, Total 13.935 22.866 25.045 22.148 19.925
Total Current Liabilities 277.392 368.979 175.87 41.3 42.944
Accounts Payable 14.505 16.035 24.898 8.868 9.175
Accrued Expenses 42.724 69.333 24.479 18.323 12.793
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 36.991 10.242 9.684 4.307 17.529
Other Current Liabilities, Total 183.172 273.369 116.809 9.802 3.447
Total Liabilities 401.547 646.771 371.742 129.57 86.72
Total Long Term Debt 115.39 104.413 95.767 80.909 40.07
Long Term Debt 87.227 50.726 46.375 24.317 14.272
Capital Lease Obligations 28.163 53.687 49.392 56.592 25.798
Deferred Income Tax 0.694 1.29 0.412
Other Liabilities, Total 8.071 172.089 99.693 7.361 3.706
Total Equity 219.797 170.581 77.422 135.153 143.187
Common Stock 20.755 15.786 13.646 13.642 13.638
Additional Paid-In Capital 594.043 409.258 244.984 297.732 297.72
Retained Earnings (Accumulated Deficit) -389.315 -248.671 -177.835 -170.272 -161.559
Treasury Stock - Common -0.645 -0.645 -0.898 -1.112 -1.133
Other Equity, Total -5.041 -5.147 -2.475 -4.837 -5.479
Total Liabilities & Shareholders’ Equity 621.344 817.352 449.164 264.723 229.907
Total Common Shares Outstanding 138.223 105.115 90.8242 90.8195 90.7935
Total Preferred Shares Outstanding 0.02051 17.8367 17.8367 17.8367 17.8367
Long Term Investments 0 2.124 2.13 2.263 1.122
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 389.329 424.66 476.535 503.776 545.021
Cash and Short Term Investments 254.485 286.532 261.042 336.177 311.264
Cash & Equivalents 254.485 -0.001 261.042 311.264
Total Receivables, Net 27.018 23.912 57.732 16.251 25.061
Accounts Receivable - Trade, Net 27.018 23.912 57.732 16.251 25.061
Total Inventory 38.999 35.104 96.462 95.201 139.725
Other Current Assets, Total 68.827 79.112 61.299 56.147 68.971
Total Assets 590 621.344 698.083 725.105 777.711
Property/Plant/Equipment, Total - Net 158.039 154.038 170.659 169.992 175.98
Intangibles, Net 27.896 28.711 29.652 30.714 31.765
Long Term Investments 0 0 0 2.124
Other Long Term Assets, Total 14.736 13.935 21.237 20.623 22.821
Total Current Liabilities 263.26 277.392 374.211 436.128 363.257
Payable/Accrued 33.52 41.491 74.973 83.704 66.268
Accrued Expenses 15.875 15.738 16.036 15.199 19.838
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 39.944 36.991 15.612 14.532 14.852
Other Current Liabilities, Total 173.921 183.172 267.59 322.693 262.299
Total Liabilities 385.217 401.547 533.1 631.85 629.305
Total Long Term Debt 112.784 115.39 146.007 118.989 100.668
Long Term Debt 83.228 87.227 93.364 67.058 48.005
Capital Lease Obligations 29.556 28.163 52.643 51.931 52.663
Deferred Income Tax 1.057 0.694 1.784 1.978 1.28
Other Liabilities, Total 8.116 8.071 11.098 74.755 164.1
Total Equity 204.783 219.797 164.983 93.255 148.406
Common Stock 20.752 20.755 17.603 17.603 16.17
Additional Paid-In Capital 594.043 594.043 501.638 501.638 412.799
Retained Earnings (Accumulated Deficit) -410.011 -389.315 -354.258 -419.795 -280.563
Other Equity, Total -0.001 -5.041 -5.546
Total Liabilities & Shareholders’ Equity 590 621.344 698.083 725.105 777.711
Total Common Shares Outstanding 138.223 138.223 117.276 117.276 107.727
Total Preferred Shares Outstanding 0.02051 0.02051 17.8367 17.8367
Cash 286.533 336.177
Short Term Investments
Treasury Stock - Common -0.645 -0.645
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -143.279 -73.425 -64.393 -1.744 3.264
Cash From Operating Activities -242.445 76.945 137.779 5.529 16.306
Cash From Operating Activities 21.036 14.281 9.799 8.532 6.828
Non-Cash Items -126.058 101.55 116.613 7.769 3.534
Cash Taxes Paid 0.154 1.631 2.021 2.346 1.273
Cash Interest Paid 9.211 8.417 4.711 2.621 4.165
Changes in Working Capital 5.856 34.539 75.76 -9.028 2.68
Cash From Investing Activities -29.054 -93.116 -19.34 -10.685 -2.917
Capital Expenditures -29.322 -93.171 -19.471 -10.884 -3.171
Other Investing Cash Flow Items, Total 0.268 0.055 0.131 0.199 0.254
Cash From Financing Activities 215.116 154.504 21.74 -7.696 30.945
Financing Cash Flow Items -9.211 -8.417 -4.71 -2.621 -4.165
Issuance (Retirement) of Stock, Net 189.837 166.823 0.29 -2.463 49.263
Issuance (Retirement) of Debt, Net 34.49 -3.902 26.16 -2.612 -14.153
Foreign Exchange Effects -0.828 3.96 -0.183 0.207 -0.795
Net Change in Cash -57.211 142.293 139.996 -12.645 43.539
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.127 -143.279 -99.075 -171.493 -26.041
Cash From Operating Activities -24.326 -242.445 -186.562 -100.18 -26.806
Non-Cash Items 8.438 -126.058 17.784 -5.481 -6.922
Cash Taxes Paid 0.433 0.154 1.082 0.818 0.318
Cash Interest Paid 2.689 9.211 6.544 4.054 1.909
Changes in Working Capital -14.637 5.856 -105.271 65.641 6.157
Cash From Investing Activities -3.561 -29.054 -22.483 -15.994 -9.447
Capital Expenditures -3.814 -29.322 -22.541 -16.028 -9.461
Other Investing Cash Flow Items, Total 0.253 0.268 0.058 0.034 0.014
Cash From Financing Activities -3.816 215.116 121.631 105.006 0.982
Financing Cash Flow Items -2.689 -9.211 -6.544 -4.054 -1.909
Issuance (Retirement) of Stock, Net -0.194 189.837 93.998 94.308 3.726
Issuance (Retirement) of Debt, Net -0.933 34.49 34.177 14.752 -0.835
Foreign Exchange Effects -0.344 -0.828 1.814 0.751 -0.107
Net Change in Cash -32.047 -57.211 -85.6 -10.417 -35.378
Cash From Operating Activities 21.036 11.153

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Valneva SE Company profile

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Financial summary

BRIEF: For the six months ended 30 June 2021, Valneva SE revenues decreased 1% to EUR47.5M. Net loss applicable to common stockholders increased from EUR25.6M to EUR86.4M. Revenues reflect Commercialized Vaccines segment decrease of 22% to EUR31.8M, Canada segment decrease of 75% to EUR2M, United Kingdom segment decrease of 75% to EUR1.1M, Europe excluding France segment decrease of 42% to EUR4.2M.

Equity composition

07/2010, Rights Issue, 2 new shares for every 5 shares held @ EUR 5.06 (Factor: 1.12817). 6/2013, Rights Issue, 5 new shares for every 13 shares held @ EUR2.65 (Factor: 1.11881). 1/2015, Rights Issue, 11 new shares for every 34 shares held @ EUR2.47 (Factor: 1.10896).

Industry: Biotechnology & Medical Research (NEC)

6 rue Alain Bombard
SAINT-HERBLAIN
PAYS DE LA LOIRE 44800
FR

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

XRP/USD

0.52 Price
-3.590% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

27,121.75 Price
+0.660% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

90.04 Price
-1.230% 1D Chg, %
Long position overnight fee 0.0661%
Short position overnight fee -0.0881%
Overnight fee time 21:00 (UTC)
Spread 0.030

ETH/USD

1,683.75 Price
+0.780% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading